Kindstar Globalgene Technology (HKG:9960) expects to record a loss of between 55 million yuan and 65 million yuan for the year 2024, compared with a profit of 36.4 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.
The clinical testing company attributed the loss mainly to high credit-impaired losses, a loss from the fair value change on fund investments needing to be recognized, and an effect on its operating leverage and scale effect due to a slowdown in demand and market changes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.